

osteolabs GmbH
Company
|
Germany, Kiel
Primary tabs
About your organization / profile
Calcium Isotope Marker Technology: A novel, highly sensitive diagnostic platform for early detection of bone-related disorders
- Our mission: Turn Coral Research into Clinical Diagnostics for > 1 Billion patients lacking efficient tools for Early Diagnosis of bone-related disorders with a high unmet need.
- Calcium Isotope Marker (CIM) technology provides highly sensitive insights into Bone Calcium Balance (BCaB)/Calcium Homeostasis through measurement of 44Ca/42Ca Isotope Fractination representing a noel & universal Biomarker Class as single test principle for highly burdensome diseases.
- Significant clinical validation with over 3,000 samples for fracture risk prevention, detection and monitoring but also early detection of Bone Metastases through use of newly developed ProstaTest.
- Newly developed RenaTest: Correct classification of CKD patient status and early detection of Renal Osteodystrophy.
- With a strong team of 20+ people in place we have started to execute our Business Plan with focus on Scale-up and rapid Market Penetration of all test formats in order to address multimillion/billion market opportunities.
- CIM technology has clear 100M+ revenue potential over next 10 years with appropriate financial backing and hence represents an attractive investment opportunity before take-off.
Network (0)
There are no organizations in the network.
Recent activities

osteolabs GmbH is now a member of the EIC ACCESS+ community.

osteolabs GmbH is now a member of the EEN2EIC - Seal of Excellence community.

osteolabs GmbH is now a member of the TechGlow EU community.

Dr. Michael Lutz has joined osteolabs GmbH.

Kathrin Hagen has joined osteolabs GmbH.